Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: Current status

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 769-773

  Li, Weibin ^a,b   Wang, Kaiyu ^b   Zhao, Meng ^b   Yang, Xiangyue ^b   Chen, Min ^b   Lan, Xiaopeng ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Fuzhou General Hospital of Nanjing Military Command   (China)

Author keywords

Anticoagulants; Antithrombotics; Aptamer; Cardiovascular diseases

Indexed keywords

ANTICOAGULANT AGENT; APTAMER; ARC 1172; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 9; EGAPTIVON PEGOL; HD 1 22; NU 172; OLIGONUCLEOTIDE; PEGNIVACOGIN; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DRUG DEVELOPMENT; METABOLISM; PROCEDURES;

ANIMALS; ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; FACTOR IX; FACTOR XII; HUMANS; THROMBIN; VON WILLEBRAND FACTOR;

EID: 84908219451     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.021     Document Type: Review

References (58)

1. Jackson SP, Schoenwaelder SM. Anti-platelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003;2:775-89.
2. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008;5:766-80.
3. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010;159:502-17.
4. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al. JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, withclopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to BlockPlatelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-73.
5. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to moreefficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30.
6. Schömig A. Ticagrelor is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;10(361):1108-11.
7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
8. Bae ON. Targeting von Willebrand Factor as a Novel Anti-platelet Therapy; Application of ARC1779, an Anti-vWF Aptamer, against Thrombotic Risk. Arch Pharm Res 2012;35:1693-9.
9. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-22.
10. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249:505-10.
11. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007;14:283-91.
12. Han K, Liang Z, Zhou N. Design strategies for aptamer-based biosensors. Sensors (Basel) 2010;10:4541-57.
13. Dollins CM, Nair S, Sullenger BA. Aptamers in immunotherapy. Hum Gene Ther 2008;19:443-50.
14. Ng EW, Shima DT, Calias P, Cunningham Jr ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32.
15. Whatley AS, Ditzler MA, Lange MJ, Biondi E, Sawyer AW, Chang JL, et al. Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA Aptamers. Mol Ther Nucleic Acids 2013;2:e71.
16. Wang J, You M, Zhu G, Shukoor MI, Chen Z, Zhao Z, et al. Photosensitizer-Gold Nanorod Composite for Targeted Multimodal Therapy. Small 2013;9:3678-84.
17. Jalalian SH, Taghdisi SM, Shahidi Hamedani N, Kalat SA, Lavaee P, Zandkarimi M, et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci 2013;50:191-7.
18. Hwang B, Han K, Lee SW. Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. FEBS Lett 2003;548:85-9.
19. Lancellotti S, De Cristofaro R. Nucleotide-derived thrombin inhibitors: a new tool for an old issue. Cardiovasc Hematol Agents Med Chem 2009;7:19-28.
20. Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost 2005;3:1861-72.
21. Adams E, Huntington JA. Thrombin-cofactor interactions structural insights into regulatory mechanisms. Arterioscler Thromb Vasc Biol 2006;26:1738-45.
22. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355:564-6.
23. Macaya RF, Schultze P, Smith FW, Roe JA, Feigon J. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci U S A 1993;90:3745-9.
24. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005;106:2605-12.
25. Tasset DM, Kubik MK, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 1997;272:688-98.
26. Schwienhorst A. Direct thrombin inhibitors -a survey of recent developments. Cell Mol Life Sci 2006;63:2773-91.
27. Müller J, Freitag D, Mayer G, Pötzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 2008;6:2105-12.
28. Pendergrast PS, Marsh HN, Grate D, Healy JM, Stanton M. Nucleic Acid Aptamers for Target Validation and Therapeutic Applications. J Biomol Tech 2005;16:224-34.
29. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-13.
30. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LL. In vivo anticoagulant properties of a novel nucleotidebased thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993;81:3271-6.
31. DeAnda Jr A, Coutre SE, Moon MR, Vial CM, Griffin LC, Law VS, et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Surg 1994;58:344-50.
32. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2011;5:33-59.
33. Long SB, Long MB, White RR, Sullenger BA. Crystal structure of an RNA aptamer bound to thrombin. RNA 2008;14:2504-12.
34. Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation.Technology, development and clinical application. Thromb Haemost 2005;93:1014-20.
35. Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Sem Thromb Haemost 1987;13:514-27.
36. Nordoy A. Haemostatic factors in coronary heart disease. J Intern Med 1993;233:377-83.
37. Huang RH, Fremont DH, Diener JL, Schaub RG, Sadler JE. A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1. Structure 2009;17:1476-84.
38. Diener JL, Daniel Lagasse HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009;7:1155-62.
39. Efficacy of ARC1779 in the cynomolgus monkey model of electrical injury-induced occlusive arterial thrombosis. Nonclinical technical repor. Cambridge, Mass: Archemix; 2006 [vWF-PHARM-008-06:1-77].
40. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678-86.
41. Arzamendi D, Dandachli F, Theoret JF, Ducrocq G, Chan M, Mourad W, et al. An anti-von Willebrand Factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Clin Appl Thromb Hemost 2011;17:E70-8.
42. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy: A Randomized Trial. Stroke 2011;42:2149-53.
43. Lowe GD. Factor IX, and thrombosis. Br J Haematol 2001;115:507-13.
44. Smith SB, Gailani D. Update on the physiology and pathology of factor IX activation by factor XIa. Expert Rev Hematol 2008;1:87-98.
45. Schmidt AE, Bajaj SP. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc Med 2003;13:39-45.
46. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006;114:2490-7.
47. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, et al. Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease. Eur Heart J 2011;32:2412-9.
48. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous intervention. Circulation 2010;122:614-22.
49. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J 2011;32:2412-9.
50. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J 2013;34:2481-9.
51. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010;125:210-5.
52. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143-56.
53. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007;104:6388-93.
54. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-18.
55. van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, et al. Dual role of collagen in factor XIIdependent thrombus formation. Blood 2009;114:881-90.
56. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 1992;267:19691-7.
57. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-81.
58. Woodruff RS, Xu Y, Layzer J, Wu W, Ogletree ML, Sullenger BA. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost 2013;11:1364-73.